-
Professor David Curtis Elaborates on the Breakthrough Results of the ALLG BM12 CAST Study丨EHA 2025
The 30th European Hematology Association (EHA) Annual Meeting 2025 was grandly held in Milan, Italy, gathering top experts from the global hematology community to discuss and share the latest research progress and cutting-edge technologies in the field. During the Plenary Session, Professor David Curtis from the Australasian Leukaemia and Lymphoma Group (ALLG), on behalf of…
-
Subverting Traditional Concepts: CLL Does Not Originate from a Single Clone; Multiple Independent Minor Clones Plant the “Seeds” Early On丨EHA 2025
The 2025 European Hematology Association (EHA) Annual Meeting was grandly held both online and in person, gathering top experts and cutting-edge research from the global hematology community. At this conference, a revolutionary study on the origin of Chronic Lymphocytic Leukemia (CLL) attracted widespread attention. A research team from Spain, using multi-omics single-cell sequencing technologies, revealed…
-
Professor Jakob Kather Elaborates on the Evolution and Future Prospects of AI in Hematologic Oncology丨EHA 2025
The 2025 European Hematology Association (EHA) Annual Meeting was held in a hybrid format, both online and in-person, gathering top experts and scholars from the global hematology community. The conference focused on the deep integration of cutting-edge technology and clinical practice, with the application of Artificial Intelligence (AI) being one of the core topics. Professor…
-
Professor John Mascarenhas Details Breakthrough Safety and Efficacy Data of INCA33989 in Patients with ET丨EHA 2025
The 2025 European Hematology Association (EHA) Annual Meeting was recently held, bringing together top global experts in the field of hematologic malignancies to discuss the latest research findings and future directions. In the highly anticipated “Late-Breaking Abstract” session, Professor John Mascarenhas from the Icahn School of Medicine at Mount Sinai presented clinical study data on…
-
HCT Frailty Scale Pioneers a New Paradigm in Pre-transplant Assessment: Precisely Predicting Prognosis and Optimizing Patient Management丨EHA 2025
Opportunities and Challenges in Allogeneic Transplantation: The Urgent Need for Precise Assessment Professor Maria Queralt Salas pointed out at the beginning of her report that as a potentially curative therapy,…
-
Professor Shaji Kumar Details the Breakthrough Application of Talquetamab plus Teclistamab in Relapsed/Refractory Multiple Myeloma with Extramedullary
Extramedullary Disease: The “Solid Ice” of Multiple Myeloma Treatment Multiple myeloma is a hematologic malignancy characterized by the abnormal proliferation of plasma cells in the bone marrow. However, when these…
-
In-depth Analysis of the Background and Core Issues of the EHA Guidelines for Mild-to-Moderate Hemophilia A/B丨2025 EHA Guidelines Meeting
Introduction: Challenging Traditional Cognition, The Systematic Layout of the EHA Guidelines Committee At the beginning of the meeting, Professor Steffen Koschmieder from Aachen, Germany, a member of the EHA Guidelines…
-
EHA-EMN 2025 Guidelines Reshape the Multiple Myeloma Treatment Landscape: Quadruplet Regimens and Immunotherapies Lead a New Era丨EHA 2025
Guideline Update Background: Addressing the Unprecedented Complexity of Treatment Choices At the beginning of the meeting, Professor Peter Sonneveld, President of EHA-EMN, delivered the opening remarks. He pointed out that…
Connecting Medical Expertise through Media